retatrutide and autoimmune disease Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results Triple hormone receptor agonist retatrutide

Molecular Architecture Why Asymmetric Receptor Affinity is by Design Tirzepatide is not a balanced dual agonist in the strict pharmacological sense, its binding affinities at GIPR and GLP-1R differ by roughly an order of magnitude, and this imbalance is the result of deliberate engineering rather than synthetic limitation

But like anything that affects your hormones, side effects can happen

Pharmacotherapy of obesity: available medications and drugs under investigation

If you're taking these alongside GLP-1 therapy, they may be responsible for urinary changes

There is a growing interest in using GLP-1RAs as a therapeutic agent for the treatment of motivation and reward-related behavioral disorders

Other melanocortin receptors like MC3R, MC4R, and MC5R exist, but MC1R is the main target related to skin pigmentation